Filing Flows › Pacira BioSciences (PCRX) › Q3 2026
Pacira BioSciences (PCRX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Pacira BioSciences (PCRX) reported revenue of $177M for the third quarter 2026 (Q3 2026), -2% from a year earlier and -8% from the quarter before. Operating margin was 12.6%, net earnings $28.5M (16.1% of revenue).
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $177M | -8% | -2% |
| Operating profit | $22.3M | +422% | +250% |
| Net earnings | $28.5M | +513% | +425% |
| Operating cash flow | $50.1M | -13% | -18% |
| Free cash flow | $46.4M | -17% | -18% |
What changed
Revenue was $176.7M in Q3 2026, down 2% year over year and down 8% from the previous quarter. EXPAREL was the largest line at 81% of revenue. iovera° lost $4.5M year over year (down 69%), 157% of the total change.
Operating profit was $22.3M, a 12.6% margin (up 9.1 points year over year). Total costs fell 11% while revenue fell 2%. Net earnings were $28.5M, up 425% year over year. The effective tax rate was 1.0%. Non-operating items added $6.5M, 23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $50.1M (down 18% year over year), 176% of net earnings. Non-cash charges added back $19.3M of depreciation and amortization and $11.8M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $3.6M left free cash flow of $46.4M.
Questions
What was Pacira BioSciences' revenue in the third quarter 2026?
Pacira BioSciences (PCRX) reported revenue of $177M for the third quarter 2026 (Q3 2026), -2% from a year earlier and -8% from the quarter before.
Was Pacira BioSciences profitable in the third quarter 2026?
Operating profit was $22.3M (12.6% of revenue) and net earnings $28.5M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.